DBV Technologies S.A. reported results for the quarter ended 2026 with revenue of $700K, a net loss of ($50.4M) and diluted loss per share of ($0.12), versus revenue of $1.5M, a net loss of ($41.9M) and diluted loss per share of ($0.31) in the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$700K$1.5M(53.3%) | Net income²($50.4M)($41.9M)(20.3%) | Diluted EPS³($0.12)($0.31)61.3% |
¹ Reported as “Operating income”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per share attributable to shareholders”.
Business Highlights
- Regulatory progress: BLA for VIASKIN® Peanut (ages 4–7) planned for Q3 2026 after iterative FDA feedback; no new data requested.
- Clinical momentum: Ongoing Phase 3 toddler safety study and initiation of a Phase 2 THRIVE study in infants (6–12 months) to support potential label expansion.
- Commercial readiness: Signed LOIs with Fareva and ICS for commercial manufacturing and U.S. distribution support and planned manufacturing investments.
- Operational shift: Increased headcount and U.S. commercial, regulatory, quality and launch spending to prepare for potential approval.
- Cash and planning: Cash runway supports operations into Q3 2027; company is prioritizing cost containment and aligning timing with the BLA schedule.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.